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Golgi apparatusUnlike the synthesis of other membrane lipids, sphingolipid synthesis is compartmentalized between the
endoplasmic reticulum and the Golgi apparatus. The initial steps of sphingolipid synthesis, from the activity of
serine palmitoyltransferase through to dihydroceramide desaturase, take place in the endoplasmic reticulum,
but the further metabolism of ceramide to sphingomyelin and complex glycosphingolipids takes place mostly
in the Golgi apparatus. Studies over the last decade or so have revealed unexpected levels of complexity in
the sphingolipid biosynthetic pathway, mainly due to either the promiscuity of some enzymes towards their
substrates, or the tight selectivity of others towards speciﬁc substrates. We now discuss two enzymes in this
pathway, namely serine palmitoyltransferase (SPT) and ceramide synthase (CerS), and one lipid transport
protein, CERT. For SPT and CERT, signiﬁcant structural information is available, and for CerS, signiﬁcant information
has recently been obtained that sheds light of the roles of the speciﬁc ceramide species that are produced by each of
the CerS. We consider the mechanisms by which speciﬁcity is generated and speculate on the reasons that
sphingolipid biosynthesis is so complex. This article is part of a Special Issue entitled: Functional and structural
diversity of endoplasmic reticulum.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The endoplasmic reticulum (ER) is the major site of membrane
lipid biosynthesis in mammalian cells. All three major membrane
lipid classes, namely glycerolipids, sterols and sphingolipids (SLs),
begin their lives in the ER prior to their removal and subsequent
transport to the distinct sub-cellular localizations where they reside
[1]1. However, SLs are unique among membrane lipids inasmuch as
a number of their biosynthetic steps take place in the Golgi apparatus.
This review will focus on SL biosynthesis in the ER, and in particular,
on the biosynthesis of dihydroceramide and ceramide, the backbone
of all complex SLs [2], and on the transport of ceramide from the ER
to the Golgi apparatus.
2. SL structure
Ceramide (Fig. 1) is generated de novo in the ER by a biosyn-
thetic pathway that begins with the condensation of L-serinecial issue on “Functional and
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ing 3-ketosphinganine [2]. However, over the past few years, a
number of other amino acids and fatty acyl CoAs of varying chain
lengths have been shown to act as substrates for SPT (see below).
3-Ketosphinganine is subsequently reduced to sphinganine via
3-ketosphinganine reductase. This is followed by N-acylation of
sphinganine (where the ‘N’ signiﬁes that acylation takes place
on the free amino group of sphinganine) via sphinganine N-acyl
transferase to form dihydroceramide, and subsequent reduction
of dihydroceramide to ceramide by dihydroceramide desaturase.
Sphinganine N-acyl transferase can also use sphingosine as sub-
strate (sphinganine and sphingosine differ by the presence of a
trans double bound in the 4,5 position, which is found in sphingo-
sine but not in sphinganine); evidence is accumulating that this
N-acyl transferase is relatively promiscuous with respect to the
sphingoid long chain base, whereas it is highly speciﬁc towards
the length of the acyl chain, as discussed in detail below. The
N-acyl transferase has become known generically as ‘ceramide
synthase’ (CerS) [3]; formally, this enzyme should be known as
(dihydro)ceramide synthase, since it converts sphinganine to
dihydroceramide in the biosynthetic pathway in the ER but can
also convert sphingosine derived from the degradative pathway di-
rectly to ceramide; however, the generic name, CerS, has become
most well-used.
After formation of ceramide in the ER, most subsequent steps of SL
biosynthesis take place in the Golgi apparatus [4]. Interest in the
mode of transport of ceramide from the ER to the Golgi apparatus was
sparked in the early 2000s by the discovery of the ceramide transfer
Fig. 1. The pathway of sphingolipid biosynthesis. The left-hand panel shows the pathway of SL biosynthesis, with enzymes indicated in italics, and the right-hand panel shows the
structure of ceramide. Each number in the left-hand panel corresponds to a chemical reaction in the right-hand panel, with the exception of step 5, which refers to the ability of
CERT to remove ceramide from the ER and deliver it to the Golgi apparatus. Note that step 6 includes formation of SM, GlcCer or GalCer.
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ER for the synthesis of sphingomyelin (SM) in the lumen of the
Golgi apparatus; the current consensus is that glucosylceramide
(GlcCer), which is also synthesized in the Golgi apparatus, but on
the cytosolic surface [7], utilizes ceramide derived from vesicular
transport from the ER.
This review will focus on three critical steps of SL synthesis; the
initial step of SL formation by SPT (step 1 in Fig. 1), the N-acylation
of sphingoid long chain bases (step 3 in Fig. 1), and the removal of
ceramide from the ER (step 5 in Fig. 1). Work over the past decade
or so has led to many unexpected ﬁndings about the complexity of
each of these steps. In parallel, lipidomics studies have uncovered
many more individual SL structures than previously assumed [2].
We will focus on the major mechanisms by which this diversity
is generated in the three steps mentioned above. In the case of
SPT and CERT, signiﬁcant structural information is available which
impacts upon our understanding of how this diversity is generated,
but much less structural information is available for the CerS.
3. SPT — it's not all in the name
As mentioned above, and as implied by its name, SPT is usually
considered to use L-serine and palmitoyl-CoA for the formation of
3-ketosphinganine, even though studies performed nearly 30 years
ago suggested that other fatty acyl CoAs could also be utilized by SPT
[8]. SPT, the rate-limiting step in SL biosynthesis [9,10], belongs to the
α-oxoamine synthase family and is pyridoxal 5′-phosphate-dependent
[11]. SPT activity can bemodulated by the use of speciﬁc inhibitors, such
as myriocin [9,10], or by modifying substrate supply by enhancing the
rate of amino acid import [12,13].
SPT is a heteromeric protein located in the ER of eukaryotic cells, but
located in the cytoplasmof the gram-negative bacterium, Sphingomonas
paucimobilis [14]; the latterwas the source of the enzymeused to deter-
mine the ﬁrst crystal structure of SPT [14]. Structural studies revealed
that the pyridoxal 5′-phosphate cofactor binds covalently to a lysine
residue (Lys265) and that the active site comprises residues from both
SPT subunits [14]. The two mammalian SPT subunits are known as
long chain bases 1 and 2 (LCB1/LCB2) or as SPT1 and SPT2 [15,16],with SPT2 found as two isoforms (LCB2a and LCB2b (also known
as SPT3)) [17,18]; LCB1 and LCB2 knock-out mice are embryonically
lethal while conditional knock-outs are available [19–21]. The SPT
heterodimer can also associate with other small subunits; in yeast,
Tsc3p is required for maximal SPT activity [22] and in mammals,
two subunits, ssSPTa and ssSPTb (small subunits of SPT), substan-
tially enhance SPT activity [23]. Combinations of different subunits
confer different speciﬁcities towards acyl CoAs [23]. Thus, the com-
plex of LCB1/LCB2a/ssSPTa shows a strong preference for C16-CoA
(palmitoyl CoA), whereas LCB1/LCB2b/ssSPTa can also use C14-CoA
(myristoyl CoA), and ssSPTb confers speciﬁcity towards C18-CoA
(stearoyl CoA) [23]. Another study suggested that LCB2b is responsi-
ble for the generation of C14- and C16-sphingoid bases, making
LCB2b functionally distinct from the LCB2a subunit [24]. In addition,
sphingoid long chain bases with a chain length of 16 carbons dem-
onstrate limited N-acyl chain diversity, generated mainly by CerS1
(see below) [25]. Thus, SPT can use at least three different acyl CoAs for
formation of 3-ketosphinganine depending on the combination of the
subunits.
Serine is not the only amino acid to be used by SPT, as recent stud-
ies have suggested that mutant forms of SPT are able to utilize alanine
and glycine [26,27]. This was discovered after the unravelling of the
molecular basis of hereditary sensory neuropathy type I (HSAN1),
an autosomal dominant genetic disorder caused by mutations in SPT
[23,28–30]. Initially it was thought that mutant SPT was inactive
and that the basis of HSAN1 was haplo-insufﬁciency [29,31]. How-
ever, more recently it was shown experimentally that a mutation
causing structural perturbations (C133W) [10] in LCB1 alters the
speciﬁcity of SPT such that it uses alanine, rather than serine, to gen-
erate 1-deoxysphinganine [31,32]. Remarkably, oral administration of
L-serine prevented accumulation of deoxysphinganines and alleviated
HSAN1 symptoms [33]. Deoxysphinganines are found at low levels in
normal individuals [34] suggesting that wild type SPT can use amino
acids other than L-serine [35]. Moreover, SPT was shown to form a
complex with the Orm family proteins [36]. Orm1 and Orm2 are
ER membrane proteins, which play central role in lipid homeostasis.
In their absence, long chain bases accumulate [37]. In summary,
together with the fact the amino acid and acyl CoA speciﬁcity of SPT
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in ways that are far more complex than originally thought.Fig. 3. Putative CerS topology andminimum region needed for speciﬁcity. Two putative
membrane topologies of the CerS are shown, with the upper panel indicating six trans-
membrane domains (adapted from Ref. [49]) and the lower panel a suggested topology
with only ﬁve transmembrane domains. In both possible structures, regions in blue are
not involved in speciﬁcity, whereas the regions in pink are involved in speciﬁcity. The
dotted line indicates the Hox-like domain; diagonal lines indicate the beginning and
end of the TLC domain and the Lag1p motif.4. Ceramide synthases — speciﬁcity, speciﬁcity, speciﬁcity
Whereas the speciﬁcity of SPT is generated either by modifying its
subunit composition or mutating speciﬁc residues, the speciﬁcity of
the mammalian CerS is inherent to each of the six CerS (Fig. 2),
which are unique gene products located on different chromosomes
[3]. Thus, CerS1 uses C18-CoA for N-acylation of the sphingoid long
chain base [38], CerS4 uses C18-C22-CoAs [39], CerS5 and CerS6
mainly use C16-CoA [39,40] and CerS3 uses C26-CoA and higher
[41]. CerS2 utilizes very-long acyl chain CoAs (i.e. C22 to C24) [42].
When the ﬁrst mammalian CerS, CerS1 (then known as uog1 based
on its homology to yeast Lag1), was discovered [38], it was clear
that other CerS had to exist, since mammalian ceramides and SLs
were known to contain a wide variety of fatty acids [2], but CerS1
only generated C18-ceramide; however, the number of CerS, and
their roles in diverse biological processes, have been one of the sur-
prises in the SL ﬁeld in the last decade [43]. Interestingly, the CerS
seem quite promiscuous towards the sphingoid long chain base
since they are able to N-acylate a number of long chain bases or deriv-
atives thereof, such as fumonisin B1 [44], NBD-sphinganine [45] and
FTY720 [46].
Despite their crucial roles in SL synthesis, the CerS are much
less-well characterized than SPT, with little information available
about their substrate binding sites and mode of selectivity towards dif-
ferent acyl CoAs [43]. CerS are integral membrane proteins located in
the ER [47], with their active sites probably facing the cytosol [48]. How-
ever, the transmembrane topology of the CerS has not been resolved
experimentally. Comparison of several prediction programs to assess
topology [49] suggests that the CerS have six membrane-spanning
domains, but signiﬁcant disagreements between the various prediction
programs exist for the 4th putative transmembrane domain (Fig. 3),
with some programs indicating one membrane-spanning domain and
others two; an odd-number of trans-membrane domains is supported
by recent experimental data [50]. Resolution of themembrane topology
of the CerS has been examined by two main experimental studies to
date [40,47] yet they are far from conclusive.
Even though the CerS are unique gene products, they display a sig-
niﬁcant homology in their primary sequence (Fig. 2). All CerS share a
unique domain, the Tram-Lag-CLN8 (TLC) domain, a region of ~200
residues also found in other proteins [3]. The Lag1p motif, which is
found within the TLC domain, is a conserved stretch of 52 amino
acids that is not found in the two other TLC domain-containing fami-
lies (TRAM and CLN8). The Lag1p motif has been suggested to be es-
sential for CerS activity and contains a number of residues, including
two conserved histidines, which may be involved in catalysis or sub-
strate binding [47,51]. An additional feature shared by mammalian
CerS (with the exception of CerS1) is the homeobox (Hox)-like
domain, of which the last 12 residues are critical for activity [52].Fig. 2. Ceramide synthases. The current name of each CerS is shown, along with the fatty acy
knock-out mice are available are indicated along with the main phenotype.However, the precise function of the Hox-like domain is not
known [53].
We recently deﬁned a minimum region required for CerS acyl CoA
speciﬁcity [49] by generating chimeric proteins consisting of different
regions of CerS5 and CerS2; these CerS were chosen since they have
widely-differing substrate speciﬁcities. A minimal region of 150 resi-
dues within the TLC domain was identiﬁed as being sufﬁcient for
maintaining acyl CoA speciﬁcity. In CerS5, this region is comprised
of residues 159–309 and is sufﬁcient for maintaining speciﬁcity
towards C16-CoA, while the equivalent region in CerS2 comprises
residues 151–301, which is sufﬁcient to maintain C22/C24-CoA spec-
iﬁcity. While only 150 residues are needed for acyl CoA speciﬁcity, it
is clear that the remainder of the protein is required to maintain the
three dimensional structure of the enzyme, and presumably to hold
the region required for speciﬁcity in the right conformation. Similar
studies to identify the regions of speciﬁcity towards the long chain
base are not available, though the sphingoid long chain base binding
site appears much more accommodating to structural variations than
the acyl CoA binding site.
One of the questions that have entertained the SL ﬁeld concerns
whether SL synthesis in the ER occurs via a multi-protein complex,
or whether each enzyme acts independently of each other. There isl CoAs that it uses to synthesize ceramides of speciﬁc chain length. Those CerS for which
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also with Lac1 [54], however there is currently no evidence for a mo-
lecular association between SPT, 3-ketosphinganine reductase, the
CerS and dihydroceramide desaturase, although since these proteins
share substrates and products, some of which are lipid-soluble, they
presumably are located in close proximity to one another within the
ER membrane to allow for substrate and product ﬂux. However, re-
cently evidence has been obtained that the CerS undergo hetero-
and homo-interactions by the formation of hetero- and homodimers
[50]. This possibility was ﬁrst raised by the observation that CerS
mRNA expression and enzymatic activity do not always correlate with
the SL acyl chain composition of a particular tissue [42], suggesting
post-translational mechanism(s) of regulation of CerS activity. This
may also be the case in yeast where overexpression of Lag1, Lac1 or
mammalian CerS5 does not lead to a large increase in CerS activity,
while expression of mammalian CerS6 or of a cotton CerS leads to
higher elevation of activity [55,56]. CerS can be phosphorylated [57]
and glycosylated [40], and it was suggested that CerS2, 5, and 6 exist
as heterocomplexes in HeLa cells [58]. Using a variety of approaches,
including co-expression, co-immunoprecipitation and generation of
constitutive dimers, we demonstrated that CerS activity could be mod-
ulated by dimer formation. The most exciting result was obtained upon
use of a heterodimer consisting of one monomer of CerS5 and another
of CerS2, in which the activity of CerS2 depends on the catalytic activity
of CerS5, demonstrating that optimal CerS2 activity depends on an in-
teraction with a catalytically-active form of CerS5. Based on this result,
we suggested amodel inwhich the binding of a substrate to onemono-
mer of the dimer allosterically affects binding to the other monomer.
This result has signiﬁcant implications for the CerS ﬁeld, as it implies
that the acyl chain composition of ceramide (and consequently of
down-stream SLs) does not simply reﬂect the CerS expression pattern
in a particular tissue, but will rather depend on the combinatorial ex-
pression of the different CerS and their ability to interact. Moreover,
CerS splice variants [3], some of whichmay have activity by themselves,
could act in a dominant-negative manner to regulate CerS activity.
Within the past 3–4 years, study of CerS biology has progressed
relatively rapidly, largely due to the generation of CerS null mice.
In all cases, the resulting phenotypes appear to be directly related to
the loss of the speciﬁc ceramide species (and up-stream SLs) that
are generated by the particular CerS that was deleted, but the possi-
bility that some effects are due to loss of interactions among the
CerS proteins themselves cannot be excluded. The ﬁrst CerS to be
knocked out was CerS2 [59–61], followed by CerS1 [62,63] (although
one of these [63] was a spontaneous mutation), and more recently,
CerS3 [64].
Most data is available about the effect of depleting CerS2. CerS2
synthesizes very-long (C22–24) chain ceramides, and in all tissues ex-
amined, very-long (C22–C24) ceramides and SLs were totally depleted
[59,65]. However, unexpectedly, levels of long chain (i.e. C16 and C18)
ceramides and SLs were elevated, presumably to compensate for the
loss of very-long chain ceramides. The mechanism bywhich this occurs
is not yet known, and nor is the mechanism known by which
sphinganine is elevated. Thus, deciphering the exact molecular mecha-
nisms causing pathology in CerS2 null mice is complicated by alter-
ations in levels of three classes of lipids, namely loss of very-long
chain ceramides, elevation of long chain, and elevation of sphinganine.
Moreover, some of the pathologies might also be caused by changes in
levels of speciﬁc up-stream SLs. Examples of these are the changes in
myelin structure observed in the CerS2 null mouse brain, which appear
to be caused by reduced levels of galactosylceramide [65].
Ablation of CerS2, has major effects on a number of physiological
systems, ranging from altered liver function, to lung and brain pathol-
ogies. The liver has been most well-characterized. Initially [60], CerS2
null mice were observed to develop severe non-zonal hepatopathy
from about 30 days of age, the age at which CerS2 expression peaks
in wild type mice, and display increased rates of hepatocyte apoptosisand proliferation. In oldermice, extensive and pronounced hepatocellu-
lar anisocytosis was detected, with widespread formation of nodules of
regenerative hepatocellular hyperplasia. Progressive hepatomegaly and
non-invasive hepatocellular carcinoma was seen from ~10 months of
age. High throughput analysis of mRNA expression in the liver revealed
up-regulation of genes associated with cell cycle regulation, protein
transport, cell–cell interactions and apoptosis, and down-regulation of
genes associated with intermediary metabolism, such as lipid and ste-
roidmetabolism, adipocyte signaling and amino acidmetabolism. In ad-
dition, levels of the cell cycle regulator, the cyclin dependent-kinase
inhibitor p21WAF1/CIP1, were highly elevated. Later, we demonstrated
that some of these pathologies might be caused by chronic oxidative
stress [66], although oxidative stress cannot explain all of the patholo-
gies. Levels of a number of anti-oxidant enzymes were elevated, as
were lipid peroxidation, protein nitrosylation, and ROS in the liver of
CerS2 null mice. ROS appeared to be generated from the mitochondria
due to impaired activity of complex IV of the respiratory chain [66].
C16-ceramide, sphingosine and sphinganine, the lipids whose levels
are elevated in the CerS2 null mouse, directly inhibited complex IV ac-
tivity in isolatedmitochondria and inmitoplasts. Based on these results,
we suggested that C16-ceramide and/or sphinganine induce ROS for-
mation through the modulation of mitochondrial complex IV activity,
resulting in chronic oxidative stress in the CerS2 null mouse.
In addition, CerS2 null mice exhibit glucose intolerance [67]. Both
insulin receptor and Akt phosphorylation are abrogated in liver, but
not in the adipose tissue or in the skeletal muscle. The lack of insulin re-
ceptor phosphorylation in the liver correlatedwith its inability to trans-
locate into detergent-resistantmembranes (DRMs). Moreover, DRMs in
CerS2 null mice displayed signiﬁcantly different properties to those in
wild type mice, suggesting that the altered sphingolipid acyl chain
length directly affects insulin receptor translocation and subsequent
signaling [67]. Finally, despite the severe liver pathology seen in CerS
null mice, CerS2 null mice are totally resistant to drug-induced liver in-
jury (unpublished observations), demonstrating that speciﬁc biochem-
ical pathways, rather than a general loss of liver function, are altered
upon ablation of CerS2. The biochemical pathways that are altered ap-
pear to be related in oneway or another to the altered biophysical prop-
erties of membranes, which causes defects in membrane function, as
reﬂected in the altered translocation of a number of proteins into
DRMs [67]. While we fully appreciate that DRMs are far from an ideal
tool to directly examine membrane properties, they do nevertheless
give an indication that membrane properties are altered. The altered
DRM properties are entirely consistent with alteredmembrane proper-
ties revealed by more classical biophysical techniques, such as ﬂuo-
rescence spectroscopy and microscopy. Using these techniques, a
signiﬁcant alteration in the ﬂuidity of the membrane and effects on
the type and extent of the lipid phases was observed [68], which were
a consequence of depletion of very-long chain and of unsaturated SLs,
and due to changes in intrinsic membrane curvature leading to strong
morphological alterations that promoted vesicle adhesion, membrane
fusion and tubule formation. Together, the data above support the
notion that most of the pathologies observed in CerS2 null mouse
liver are indeed a direct result of the altered SL composition which
results in altered membrane properties.
We have observed pathologies in two other tissues. First, in the
brain [65], a signiﬁcant reduction in galactosylceramide (GalCer), a
major component of myelin, was detected, which appeared to be re-
sponsible for some brain lesions, since brain lesions developed with
a time-course consistent with a vital role for C22–C24-GalCer in my-
elin stability. Myelin degeneration and detachment was observed, as
was abnormal motor behavior originating from a sub-cortical region.
This was consistent with another study [69] in which myelin lipids
from wild type mice laterally segregated into physically distinct
lipid phases in giant unilamellar vesicles, which did not occur in
CerS2 null mice. Second, signiﬁcant pathology has also been ob-
served in the lung of CerS2 null mice (unpublished observations).
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ia and Purkinje cell degeneration; this is perhaps not surprising since
CerS1 is found at high levels in the brain [39,42,70], although the
reason that Purkinje cells are speciﬁcally affected is not known.
A CerS3 mouse was also generated [64], which resulted in complete
loss of ultra-long chain ceramides and lethal skin barrier disruption.
Interestingly, a human disease resulting from CerS3 deﬁciency was
recently discovered [71] in patients with congenital ichthyosis char-
acterized by collodion membranes at birth, generalized scaling of the
skin, and mild erythroderma.
Thus, themodes of regulating the composition of both the sphingoid
long chain base, by SPT, and of the acyl chain, by CerS, have been clari-
ﬁed over the past few years. Further studies on the CerS are needed to
both understand the structural and functional basis of the ability of
the different CerS to utilize speciﬁc acyl CoAs, and to determine the
physiology effects of altering the ceramide acyl chain length, by gener-
ation of additional knock-out mice.
5. CERT — location, location, location
The conversion of ceramide to SM occurs at the inner leaﬂet of the
Golgi apparatus [72] (Fig. 4), and utilizes ceramide that is transported
via CERT from the ER [5,6]. CERT is a 68-kDa cytosolic protein also
known as a splicing variant of Good-pasture antigen-binding protein,
GPBPΔ26 [73]. CERT transports ceramide in an ATP-dependent and
non-vesicular manner [74] and is regulated by protein kinase D [75].Fig. 4. SL synthesis and transport between the ER and Golgi apparatus. The compartmentaliz
ferase; 3KSR, 3-ketosphinganine reductase; CerS, ceramide synthase; DHCD, dihydroceram
transfer protein; SMS, SM synthase; GCS, GlcCer synthase; GCﬂip, GlcCer ﬂippase; GalT1, Lac
is indicated as follows: Blue, sphingoid long chain base; thin blue line, 3-OH (as in 3-ketosph
and line, sugar head group (i.e. glucose, galactose, or GlcGal in the case of LacCer); purple rec
boxes. Further details regarding each step are given in the text.CERT levels decrease upon pro-apoptotic stress [76] and CERT is also in-
volved in certain breast cancers [77], in penetration of the pathogen
Chlamydia trachomatis [78] and in hepatitis C virus secretion [79].
Moreover, CERT is essential for embryonic survival since CERT knock-
out mice have defects in proliferation and organogenesis with underly-
ing ER and mitochondrial defects [80,81].
Signiﬁcant structural information is available about CERT. The
C-terminal contains a sequence homologous to the steroidogenic acute
regulatory protein-related lipid transfer (START) domain [6,82,83], and
the structure of the START domain has been determined [74], revealing
a long amphiphilic cavity in which one ceramide molecule is buried. At
the far end of the cavity, the amide and hydroxyl groups of ceramide
(see Fig. 1) form a hydrogen bond networkwith speciﬁc amino acid res-
idues that play key roles in stereospeciﬁc ceramide recognition. At the
end of this cavity, where the head of the ceramide molecule resides,
there is no extra space to accommodate additional bulky groups as
found in SM or GlcCer. Moreover, ceramide is surrounded by the hydro-
phobic wall of the cavity, whose size and shape dictate a length limit for
ceramides [74]. CERT appears to transfer ceramides with a chain length
of 14–20 carbon atoms better than ceramide containing longer acyl
chains (i.e. C22–C24), and can also transfer dihydroceramide and
phytoceramide [6,83,84]. The hydrophobic cavity that accommodates
the ceramide acyl chain appears to work as a molecular measuring
device similar to the bacterial membrane acyltransferase, PagP [85].
The START domain is responsible for extracting ceramide from donor
membranes and releasing ceramide to acceptor membranes [9,84].ation of SL synthesis is illustrated. Enzymes are as follows: SPT, serine palmitoyl trans-
ide desaturase; CGalT, UDP-galactose:ceramide galactosyltransferase; CERT, ceramide
Cer synthase; FAPP2, four-phosphate adaptor protein 2. A schematic of the SL structure
inganine); black, fatty acid; white line, 4,5-double bond in sphingoid base; black circle
tangle, phosphorylcholine (as in SM). Some unanswered questions are indicated in pink
2516 R. Tidhar, A.H. Futerman / Biochimica et Biophysica Acta 1833 (2013) 2511–2518The crystal structure of the START domain implicates two tryptophan
residues as being responsible for orienting the CERT START domain
relative to the membrane 1[74,86].
The N-terminus of CERT contains a pleckstrin homology (PH)
domain [73,87] that speciﬁcally binds to phosphatidylinositol 4-mono-
phosphate (PI4P). PI4P is the most abundant and preferentially-
distributed phosphoinositide in trans Golgi membranes, and the PH
domain of CERT is required for its efﬁcient association with the Golgi
via PI4P [6,88]. The three dimensional structure of the PH domain has
been determined [89] and contains a characteristic basic groove near
the PI4P recognition site [89].
A coiled-coil motif is found in the middle region of CERT (i.e. in
between the PH and START domains) together with a short peptide
motif with the consensus sequence EFFDAXE (the FFAT motif) [88].
The FFAT motifs interact with the ER-resident type II membrane pro-
teins, VAP-A and VAP-B (vesicle-associated membrane protein- asso-
ciated proteins). VAPs recruit FFAT-motif-containing proteins to the
cytosolic surface of ER membranes [90], and it is this interaction
which is crucial for the association of CERT with the ER membrane
[88,90].
Finally, membrane composition also affects the transfer activity of
CERT. Thus, if ceramide is in a tightly packed environment, such as in
SM- or dipalmitoylphosphatidylcholine- containing membranes, CERT
transfer activity is markedly reduced [91], in contrast to ceramide in
ﬂuid membranes, which is more readily available for CERT-mediated
transfer. Naturally, CERT also favors membranes that contain PI4P, due
to its PH domain [91].
6. Concluding comments
In this brief review, we have summarized current knowledge about
three key players in the SL biosynthetic pathway, two of which are
located in the ER, and one of which transfers ceramide from the ER
to the Golgi apparatus. Moreover, we have illustrated the means by
which the chemical complexity of sphingolipids is generated, which is
by a combination use of different amino acids and acyl CoAs by SPT, re-
stricted subsets of acyl CoAs for each of the CerS, and possibly transport
of speciﬁc ceramides by CERT for SM synthesis (although SMs are
known to contain both long and very-long acyl chains, with the latter
apparently less-well transported by CERT). But other levels of com-
plexity exist in the pathway. For instance, CERT speciﬁcally transfers
ceramides for SM, but not GlcCer synthesis (Fig. 4). Since SM is gener-
ated on the lumen of the Golgi, might CERT also be involved in the
trans-bilayer movement of ceramide in the Golgi apparatus? If this is
the case, then CERT would not be needed for GlcCer synthesis since
GlcCer is generated on the lumenal side of the Golgi apparatus, where
it is accessible to interact with FAPP2, which is needed for further
metabolism of GlcCer to some higher-order glycosphingolipids (Fig. 4);
interestingly, modulation of FAPP2 impacts protein vesicular transport
[92], perhaps implicating a role for GlcCer in protein transport from the
Golgi apparatus to the cell surface.
Little is currently known about whether the four enzymes of SL
synthesis located in the ER (Fig. 4) interact with each other or with
other membrane proteins. Some evidence from yeast suggests that
the yeast CerS, Lag1 and Lac1, may interact with some other ER com-
ponents, but there is no direct evidence that the proteins interact
with each other [93,94]. Moreover, nothing is known about how the
substrates and products of the various reactions are channelled
from one protein to the other, although it appears highly likely that
there is some kind of channelling. Other challenges are to understand
the mechanism of delivery of the acyl CoAs to both SPT and CerS, and
whether CERT interacts with the CerS directly or rather pick up a mol-
ecule of ceramide once it has been synthesized by the CerS and re-
leased into the membrane of the ER. These and similar questions are
important not only to sphingolipidologists, but also to all researchers
interested in understanding the regulation of ER function.Acknowledgements
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